Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis
Status:
Completed
Trial end date:
2005-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and efficacy of natalizumab in the
treatment of individuals who have been diagnosed with relapsing remitting multiple sclerosis
(MS). It is hoped that natalizumab will prevent certain types of white blood cells from
moving out of the bloodstream into organs, including the brain, that are being damaged by
autoimmune disease (a disease in which the body's own immune system attacks certain organs).
These white blood cells are thought to cause inflammation that can result in lesions (small
areas of damage) in the brain. These lesions are thought to be the cause of relapses and
disability in MS.